These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 28767562)

  • 41. SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases.
    Mizuno T; Cloyd JM; Vicente D; Omichi K; Chun YS; Kopetz SE; Maru D; Conrad C; Tzeng CD; Wei SH; Aloia TA; Vauthey JN
    Eur J Surg Oncol; 2018 May; 44(5):684-692. PubMed ID: 29551247
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for
    Tang W; Ren L; Liu T; Ye Q; Wei Y; He G; Lin Q; Wang X; Wang M; Liang F; Cui Y; Xu J
    J Clin Oncol; 2020 Sep; 38(27):3175-3184. PubMed ID: 32749938
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
    Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
    BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Coexistence of RAS and BRAF Mutations in Metastatic Colorectal Cancer: A Case Report and Systematic Literature Review.
    Afrăsânie VA; Gafton B; Marinca MV; Alexa-Stratulat T; Miron L; Rusu C; Ivanov AV; Balan GG; Croitoru AE
    J Gastrointestin Liver Dis; 2020 Jun; 29(2):251-256. PubMed ID: 32530992
    [TBL] [Abstract][Full Text] [Related]  

  • 45. RAS Mutation Is Associated with Decreased Survival in Patients Undergoing Repeat Hepatectomy for Colorectal Liver Metastases.
    Denbo JW; Yamashita S; Passot G; Egger M; Chun YS; Kopetz SE; Maru D; Brudvik KW; Wei SH; Conrad C; Vauthey JN; Aloia TA
    J Gastrointest Surg; 2017 Jan; 21(1):68-77. PubMed ID: 27334313
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genomic Sequencing and Insight into Clinical Heterogeneity and Prognostic Pathway Genes in Patients with Metastatic Colorectal Cancer.
    Kawaguchi Y; Kopetz S; Kwong L; Xiao L; Morris JS; Tran Cao HS; Tzeng CD; Chun YS; Lee JE; Vauthey JN
    J Am Coll Surg; 2021 Aug; 233(2):272-284.e13. PubMed ID: 34111531
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection.
    Molleví DG; Serrano T; Ginestà MM; Valls J; Torras J; Navarro M; Ramos E; Germà JR; Jaurrieta E; Moreno V; Figueras J; Capellà G; Villanueva A
    Carcinogenesis; 2007 Jun; 28(6):1241-6. PubMed ID: 17259658
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The ALPPS Approach for Colorectal Liver Metastases: Impact of KRAS Mutation Status in Survival.
    Serenari M; Alvarez FA; Ardiles V; de Santibañes M; Pekolj J; de Santibañes E
    Dig Surg; 2018; 35(4):303-310. PubMed ID: 29032374
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adjuvant Hepatic Artery Infusion Chemotherapy is Associated With Improved Survival Regardless of KRAS Mutation Status in Patients With Resected Colorectal Liver Metastases: A Retrospective Analysis of 674 Patients.
    Gholami S; Kemeny NE; Boucher TM; Gönen M; Cercek A; Kingham TP; Balachandran V; Allen P; DeMatteo R; Drebin J; Jarnagin W; D'Angelica M
    Ann Surg; 2020 Aug; 272(2):352-356. PubMed ID: 32675549
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Necessity of Genetic Evaluation of Metachronous Metastases of Colorectal Cancer: Quantitative Analysis of Genetic Discordance Between Metachronous Metastases and Radically Resected Primary Colorectal Cancers Using Next-Generation Sequencing.
    Lee KH; Kim JS; Kim JY
    Dis Colon Rectum; 2019 Jul; 62(7):832-839. PubMed ID: 31188184
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing.
    Kovaleva V; Geissler AL; Lutz L; Fritsch R; Makowiec F; Wiesemann S; Hopt UT; Passlick B; Werner M; Lassmann S
    Mol Cancer; 2016 Oct; 15(1):63. PubMed ID: 27756406
    [TBL] [Abstract][Full Text] [Related]  

  • 52. RAS Mutation is Associated with Unsalvageable Recurrence Following Hepatectomy for Colorectal Cancer Liver Metastases.
    Okuno M; Goumard C; Kopetz S; Vega EA; Joechle K; Mizuno T; Omichi K; Tzeng CD; Chun YS; Vauthey JN; Conrad C
    Ann Surg Oncol; 2018 Aug; 25(8):2457-2466. PubMed ID: 29786130
    [TBL] [Abstract][Full Text] [Related]  

  • 53. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.
    de Jong KP; Gouw AS; Peeters PM; Bulthuis M; Menkema L; Porte RJ; Slooff MJ; van Goor H; van den Berg A
    Clin Cancer Res; 2005 Jun; 11(11):4067-73. PubMed ID: 15930341
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The prognostic impact of RAS on overall survival following liver resection in early versus late-onset colorectal cancer patients.
    Jácome AA; Vreeland TJ; Johnson B; Kawaguchi Y; Wei SH; Nancy You Y; Vilar E; Vauthey JN; Eng C
    Br J Cancer; 2021 Feb; 124(4):797-804. PubMed ID: 33208919
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of RAS mutations on the immune infiltrate of colorectal liver metastases: A preliminary study.
    Polidoro MA; Milana F; Soldani C; Franceschini B; Anselmo A; Colombo FS; Di Tommaso L; Cimino M; Carnevale S; Lleo A; Jaillon S; Torzilli G; Donadon M
    J Leukoc Biol; 2020 Aug; 108(2):715-721. PubMed ID: 32108374
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Extended Molecular Profiling Improves Stratification and Prediction of Survival After Resection of Colorectal Liver Metastases.
    Lang H; Baumgart J; Heinrich S; Tripke V; Passalaqua M; Maderer A; Galle PR; Roth W; Kloth M; Moehler M
    Ann Surg; 2019 Nov; 270(5):799-805. PubMed ID: 31634180
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical relevance of alterations in quantity and quality of plasma DNA in colorectal cancer patients: based on the mutation spectra detected in primary tumors.
    Lin JK; Lin PC; Lin CH; Jiang JK; Yang SH; Liang WY; Chen WS; Chang SC
    Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S680-6. PubMed ID: 24841357
    [TBL] [Abstract][Full Text] [Related]  

  • 58. RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer.
    Yaeger R; Cowell E; Chou JF; Gewirtz AN; Borsu L; Vakiani E; Solit DB; Rosen N; Capanu M; Ladanyi M; Kemeny N
    Cancer; 2015 Apr; 121(8):1195-203. PubMed ID: 25491172
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial.
    Ciardiello F; Normanno N; Maiello E; Martinelli E; Troiani T; Pisconti S; Giuliani F; Barone C; Cartenì G; Rachiglio AM; Montesarchio V; Tonini G; Rizzi D; Cinieri S; Bordonaro R; Febbraro A; De Vita F; Orditura M; Fenizia F; Lambiase M; Rinaldi A; Tatangelo F; Botti G; Colucci G
    Ann Oncol; 2014 Sep; 25(9):1756-1761. PubMed ID: 24942275
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic Implication of KRAS Status after Hepatectomy for Colorectal Liver Metastases Varies According to Primary Colorectal Tumor Location.
    Sasaki K; Margonis GA; Wilson A; Kim Y; Buettner S; Andreatos N; Gani F; Amini N; Spolverato G; Pawlik TM
    Ann Surg Oncol; 2016 Oct; 23(11):3736-3743. PubMed ID: 27352204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.